Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Jul 6;75(1):42-8.
doi: 10.1212/WNL.0b013e3181e620f4.

Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept

Affiliations
Comparative Study

Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept

C M Roe et al. Neurology. .

Abstract

Objective: Several factors may influence the relationship between Alzheimer disease (AD) lesions and the expression of dementia, including those related to brain and cognitive reserve. Other factors may confound the association between AD pathology and dementia. We tested whether factors thought to influence the association of AD pathology and dementia help to accurately identify dementia of the Alzheimer type (DAT) when considered together with amyloid imaging.

Methods: Participants with normal cognition (n = 180) and with DAT (n = 25), aged 50 years or older, took part in clinical, neurologic, and psychometric assessments. PET with the Pittsburgh compound B (PiB) tracer was used to measure brain amyloid, yielding a mean cortical binding potential (MCBP) reflecting PiB uptake. Logistic regression was used to generate receiver operating characteristic curves, and the areas under those curves (AUC), to compare the predictive accuracy of using MCBP alone vs MCBP together with other variables selected using a stepwise selection procedure to identify participants with DAT vs normal cognition.

Results: The AUC resulting from MCBP alone was 0.84 (95% confidence interval [CI] = 0.73-0.94; cross-validated AUC = 0.80, 95% CI = 0.68-0.92). The AUC for the predictive equation generated by a stepwise model including education, normalized whole brain volume, physical health rating, gender, and use of medications that may interfere with cognition was 0.94 (95% CI = 0.90-0.98; cross-validated AUC = 0.91, 95% CI = 0.85-0.96), an improvement (p = 0.025) over that yielded using MCBP alone.

Conclusion: Results suggest that factors reported to influence associations between AD pathology and dementia can improve the predictive accuracy of amyloid imaging for the identification of symptomatic AD.

PubMed Disclaimer

Figures

None
Figure 1 Flow diagram for participant inclusion CDR = Clinical Dementia Rating; DAT = dementia of the Alzheimer type; GDS = Geriatric Depression Scale; nWBV = normalized whole brain volume; PiB = Pittsburgh Compound B. *Participation was tied to recruitment goals for PET PiB imaging studies.
None
Figure 2 Receiver operating characteristic (ROC) curves for all model building steps in the stepwise analysis Model step 1 is the ROC curve with mean cortical binding potential (MCBP) as the sole predictor of a dementia of the Alzheimer type diagnosis. Steps 2–6 show the area under the ROC curve with the addition of each additional significant predictor using the stepwise selection method (2 = education, 3 = physical health rating, 4 = normalized whole brain volume, 5 = gender, 6 = use of a medication that may interfere with cognition). No predictors were removed from the model after meeting the criterion for model entry. AUC = area under receiver operating characteristic curve.

References

    1. Katzman R, Terry R, DeTeresa R, et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988;23:138–144. - PubMed
    1. Crystal H, Dickson D, Fuld P, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988;38:1682–1687. - PubMed
    1. Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann Neurol 1999;45:358–368. - PubMed
    1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–319. - PubMed
    1. Mathis CA, Lopresti BJ, Klunk WE. Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol 2007;34:809–822. - PMC - PubMed

Publication types

Grants and funding